HB+ is proud to partner with the National Minority Health Association to help bring about health equity and close the disparity gap in health and healthcare for underserved, marginalized, hard-to-reach, and minority communities.

A cohort study of new users of bendroflumethiazide (BFZ) or hydrochlorothiazide plus a renin-angiotensin system inhibitor (HCTZ-RASi) found that the use of these diuretics was associated with a 2-year cumulative incidence of more than 3 percent for low blood sodium (below 130 mmol/L), also known as hyponatremia. The study is published in Annals of Internal Medicine.

Read More